GlassScriptPhysician profile
Wilhelmina D Azu
NPI 1164639217
$3,272.51
in general payments reported to CMS, 2019-2025
35 companies · $558 in 2025
The $558 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $136 · 2021: $542 · 2022: $586 · 2023: $662 · 2024: $379 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.06 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $371.97 | 2020-2025 | Veozah |
| Hologic Sales and Service, LLC | $233.77 | 2019-2024 | Acessa Provu System, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Mayne Pharma Commercial LLC | $200.85 | 2022-2025 | |
| Exeltis, USA INC. | $199.39 | 2019-2024 | Slynd |
| Evofem Biosciences, INC. | $195.18 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $167.19 | 2019-2024 | |
| Organon LLC | $154.57 | 2021-2025 | Nexplanon, Jada System |
| Bayer Healthcare Pharmaceuticals INC. | $143.71 | 2019-2025 | |
| Millicent US INC | $105.11 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Daiichi Sankyo INC. | $90.05 | 2019-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $85.15 | 2023-2024 | Myfembree |
| Medtronic, INC. | $77.92 | 2021-2022 | |
| Baxter Healthcare | $74.98 | 2021-2023 | Perclot |
| Amag Pharmaceuticals, INC. | $66.87 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $63.80 | 2021-2022 | |
| Coopersurgical, INC. | $53.86 | 2021-2023 | Mara Console, Paragard T 380a |
| Sage Therapeutics, LLC | $49.07 | 2024 | |
| Myovant Sciences INC. | $45.47 | 2021-2022 | |
| Therapeuticsmd, INC. | $44.11 | 2019-2021 | |
| Mimedx Group, INC. | $43.90 | 2025 | |
| Avion Pharmaceuticals | $40.56 | 2020-2022 | |
| Allergan, INC. | $39.69 | 2019 | |
| Roche Diagnostics Corporation | $33.76 | 2021 | |
| Vertical Pharmaceuticals, LLC | $29.86 | 2019 | |
| Lupin INC. | $28.39 | 2019 | |
| Merck Sharp & Dohme LLC | $27.13 | 2019-2020 | |
| Intuitive Surgical, INC. | $26.54 | 2025 | |
| Boston Scientific Corporation | $21.86 | 2023 | Watchman Flx |
| Smith+Nephew, INC. | $18.32 | 2024 | Pico 7 |
| Amgen INC. | $18.13 | 2025 | Evenity |
| Radius Health, INC. | $14.70 | 2019 | |
| Pharmacosmos Therapeutics INC. | $14.47 | 2021 | |
| Horizon Therapeutics Plc | $14.12 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilhelmina Azu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.